Background Serplulimab is a potential valuable therapy, while patients, physicians, and
decision-makers are uncertain about the cost-effectiveness of this novel drug and its …

Background Sintilimab plus chemotherapy significantly prolongs overall survival (OS) for
patients with advanced or metastatic oesophageal squamous cell carcinoma (OSCC) …

Background Immunotherapies can substantially improve treatment efficacy, despite their
high cost. A comprehensive overview of the cost-effectiveness analysis (CEA) of immune …

Objective Results of CameL-sq has revealed the clinical benefits to patients with advanced
squamous non-small-cell lung cancer (sq-NSCLC). This study aims to evaluate the cost …

Background A total of 11 treatment sequences for advanced wild-type squamous non-small
cell lung cancer are recommended by Chinese Society of Clinical Oncology Guidelines …

Background Sintilimab plus chemotherapy (SIDCHM) is more effective than placebo plus
chemotherapy (PLCHM) for advanced or metastatic esophageal squamous cell carcinoma …

Background This study compares first-line toripalimab with chemotherapy for advanced
nonsquamous non-small cell lung cancer (NSCLC) from the perspective of the Chinese …

Background: Esophageal cancer has a poor prognosis and currently ranks sixth in global
cancer mortality rates. The ORIENT-15 trial showed sintilimab plus chemotherapy …

Background On the basis of immunohistochemistry PD-L1 testing results, patients with
advanced non-small cell lung cancer (NSCLC) are treated differently. Theoretically, patients …

Objective The purpose of this study was to estimate the cost-effectiveness of sugemalimab
plus chemotherapy (SC) vs. placebo plus chemotherapy (PC), as the first-line treatment for …